| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-ret | 33 | 2024 | 370 | 8.740 |
Why?
|
| Neoplasms | 118 | 2024 | 15193 | 7.500 |
Why?
|
| Precision Medicine | 35 | 2023 | 1154 | 6.700 |
Why?
|
| Proto-Oncogene Proteins B-raf | 28 | 2024 | 1283 | 5.870 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 29 | 2024 | 5319 | 5.410 |
Why?
|
| Lung Neoplasms | 44 | 2024 | 11538 | 4.890 |
Why?
|
| Sarcoma | 17 | 2023 | 1725 | 4.420 |
Why?
|
| Bone Neoplasms | 25 | 2023 | 2576 | 4.300 |
Why?
|
| Pyridines | 24 | 2024 | 1244 | 4.190 |
Why?
|
| Pyrazoles | 21 | 2024 | 1471 | 4.080 |
Why?
|
| Medical Oncology | 24 | 2024 | 1423 | 3.850 |
Why?
|
| Thyroid Neoplasms | 20 | 2024 | 1866 | 3.800 |
Why?
|
| Osteosarcoma | 11 | 2023 | 929 | 3.690 |
Why?
|
| Sarcoma, Ewing | 12 | 2022 | 406 | 3.630 |
Why?
|
| Protein Kinase Inhibitors | 45 | 2024 | 4757 | 3.400 |
Why?
|
| Pyrimidines | 22 | 2024 | 3518 | 3.120 |
Why?
|
| Mutation | 72 | 2024 | 15179 | 3.100 |
Why?
|
| Immunotherapy | 22 | 2023 | 3341 | 3.070 |
Why?
|
| Humans | 323 | 2024 | 261506 | 2.880 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 65 | 2024 | 15862 | 2.860 |
Why?
|
| Antineoplastic Agents | 48 | 2023 | 14289 | 2.630 |
Why?
|
| Molecular Targeted Therapy | 32 | 2023 | 2330 | 2.610 |
Why?
|
| Oncogene Proteins, Fusion | 9 | 2021 | 755 | 2.530 |
Why?
|
| Small Cell Lung Carcinoma | 5 | 2023 | 406 | 2.530 |
Why?
|
| Radium | 6 | 2021 | 93 | 2.480 |
Why?
|
| Clinical Trials, Phase I as Topic | 15 | 2022 | 604 | 2.420 |
Why?
|
| Antineoplastic Agents, Immunological | 11 | 2022 | 1249 | 2.410 |
Why?
|
| High-Throughput Nucleotide Sequencing | 19 | 2023 | 2291 | 2.350 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 6 | 2023 | 119 | 2.320 |
Why?
|
| TOR Serine-Threonine Kinases | 16 | 2024 | 1546 | 2.260 |
Why?
|
| Pyridones | 11 | 2023 | 348 | 2.220 |
Why?
|
| Radiopharmaceuticals | 7 | 2021 | 1301 | 2.160 |
Why?
|
| Pyrimidinones | 10 | 2023 | 314 | 2.140 |
Why?
|
| Sarcoma, Alveolar Soft Part | 3 | 2023 | 75 | 2.130 |
Why?
|
| Carbolines | 7 | 2023 | 27 | 2.000 |
Why?
|
| Immunoconjugates | 6 | 2022 | 279 | 1.970 |
Why?
|
| Genomics | 15 | 2024 | 2738 | 1.920 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 216 | 1.840 |
Why?
|
| Carcinoma, Neuroendocrine | 9 | 2024 | 716 | 1.840 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 6 | 2018 | 86 | 1.740 |
Why?
|
| Bile Duct Neoplasms | 5 | 2023 | 493 | 1.570 |
Why?
|
| Cholangiocarcinoma | 5 | 2023 | 493 | 1.550 |
Why?
|
| Adult | 109 | 2024 | 77950 | 1.510 |
Why?
|
| Neoplasm Metastasis | 21 | 2021 | 5112 | 1.470 |
Why?
|
| Young Adult | 65 | 2023 | 21445 | 1.460 |
Why?
|
| Biomarkers, Tumor | 28 | 2023 | 10331 | 1.430 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2023 | 371 | 1.390 |
Why?
|
| Drug Resistance, Neoplasm | 16 | 2021 | 5178 | 1.340 |
Why?
|
| Neutropenia | 2 | 2023 | 968 | 1.340 |
Why?
|
| Female | 137 | 2024 | 141928 | 1.330 |
Why?
|
| Treatment Outcome | 64 | 2024 | 32848 | 1.320 |
Why?
|
| Anilides | 3 | 2024 | 268 | 1.310 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2020 | 167 | 1.310 |
Why?
|
| Middle Aged | 111 | 2024 | 86204 | 1.280 |
Why?
|
| Male | 124 | 2024 | 123000 | 1.280 |
Why?
|
| Oximes | 5 | 2023 | 175 | 1.250 |
Why?
|
| Leukemia, Hairy Cell | 2 | 2023 | 115 | 1.250 |
Why?
|
| Rare Diseases | 6 | 2023 | 351 | 1.250 |
Why?
|
| Positron Emission Tomography Computed Tomography | 5 | 2021 | 833 | 1.240 |
Why?
|
| Wilms Tumor | 3 | 2022 | 292 | 1.240 |
Why?
|
| Sulfonamides | 11 | 2020 | 1823 | 1.210 |
Why?
|
| Rhabdoid Tumor | 2 | 2022 | 110 | 1.210 |
Why?
|
| Circulating Tumor DNA | 4 | 2024 | 235 | 1.200 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 388 | 1.200 |
Why?
|
| Aged | 90 | 2023 | 70117 | 1.190 |
Why?
|
| Autoimmune Hypophysitis | 2 | 2018 | 13 | 1.180 |
Why?
|
| Brain Neoplasms | 7 | 2024 | 4849 | 1.180 |
Why?
|
| Benzoxazoles | 2 | 2024 | 41 | 1.170 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 2 | 2020 | 10 | 1.150 |
Why?
|
| Gene Fusion | 6 | 2024 | 209 | 1.130 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2023 | 96 | 1.120 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2024 | 221 | 1.110 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2023 | 882 | 1.100 |
Why?
|
| Carcinoma, Transitional Cell | 3 | 2022 | 962 | 1.060 |
Why?
|
| Ipilimumab | 7 | 2021 | 710 | 1.060 |
Why?
|
| Exanthema | 4 | 2024 | 211 | 1.060 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2022 | 2341 | 1.040 |
Why?
|
| Proteomics | 6 | 2015 | 1380 | 1.040 |
Why?
|
| Piperidines | 6 | 2024 | 1035 | 1.020 |
Why?
|
| Antibodies, Monoclonal | 9 | 2023 | 4367 | 1.000 |
Why?
|
| Astrocytoma | 2 | 2022 | 321 | 1.000 |
Why?
|
| Imidazoles | 7 | 2023 | 999 | 1.000 |
Why?
|
| Adolescent | 45 | 2021 | 31252 | 0.990 |
Why?
|
| Karyopherins | 2 | 2022 | 136 | 0.980 |
Why?
|
| Oncogenes | 5 | 2022 | 673 | 0.980 |
Why?
|
| Glioma | 4 | 2023 | 1963 | 0.980 |
Why?
|
| Leiomyosarcoma | 2 | 2024 | 223 | 0.970 |
Why?
|
| Clinical Trials as Topic | 15 | 2023 | 3719 | 0.970 |
Why?
|
| Adenine | 2 | 2024 | 631 | 0.950 |
Why?
|
| Sulfones | 2 | 2021 | 143 | 0.950 |
Why?
|
| Physician's Role | 2 | 2020 | 238 | 0.950 |
Why?
|
| Prognosis | 36 | 2024 | 21713 | 0.940 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2023 | 60 | 0.920 |
Why?
|
| Telemedicine | 2 | 2020 | 471 | 0.910 |
Why?
|
| Receptor, IGF Type 1 | 7 | 2016 | 347 | 0.910 |
Why?
|
| Ecosystem | 1 | 2024 | 111 | 0.900 |
Why?
|
| Physician-Patient Relations | 4 | 2019 | 792 | 0.880 |
Why?
|
| Phosphates | 1 | 2023 | 187 | 0.870 |
Why?
|
| Sirolimus | 10 | 2020 | 814 | 0.860 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2021 | 2326 | 0.860 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 3 | 2023 | 259 | 0.840 |
Why?
|
| Kidney Neoplasms | 5 | 2021 | 3022 | 0.840 |
Why?
|
| Social Media | 2 | 2023 | 203 | 0.830 |
Why?
|
| Melanoma | 10 | 2024 | 5317 | 0.830 |
Why?
|
| Metformin | 2 | 2024 | 378 | 0.820 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2021 | 1756 | 0.820 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 10035 | 0.800 |
Why?
|
| Liver Neoplasms | 10 | 2019 | 4557 | 0.800 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 119 | 0.800 |
Why?
|
| Receptor, trkC | 1 | 2021 | 15 | 0.790 |
Why?
|
| Carbazoles | 1 | 2021 | 87 | 0.790 |
Why?
|
| Antibodies, Monoclonal, Humanized | 13 | 2022 | 3251 | 0.790 |
Why?
|
| Pyrroles | 5 | 2022 | 576 | 0.790 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 22 | 0.780 |
Why?
|
| Fluorine Radioisotopes | 1 | 2021 | 133 | 0.770 |
Why?
|
| Disease-Free Survival | 19 | 2023 | 10001 | 0.770 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2023 | 297 | 0.730 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2019 | 1226 | 0.730 |
Why?
|
| Colorectal Neoplasms | 4 | 2024 | 3578 | 0.730 |
Why?
|
| Gene Rearrangement | 7 | 2024 | 783 | 0.730 |
Why?
|
| Bevacizumab | 9 | 2023 | 938 | 0.720 |
Why?
|
| Aged, 80 and over | 38 | 2023 | 29902 | 0.710 |
Why?
|
| Patient Outcome Assessment | 2 | 2020 | 245 | 0.710 |
Why?
|
| Radioimmunotherapy | 1 | 2020 | 119 | 0.710 |
Why?
|
| Retrospective Studies | 32 | 2024 | 37905 | 0.700 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2021 | 661 | 0.680 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2019 | 52 | 0.680 |
Why?
|
| Alpha Particles | 1 | 2019 | 26 | 0.670 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 860 | 0.670 |
Why?
|
| Blood-Brain Barrier | 3 | 2015 | 238 | 0.670 |
Why?
|
| Everolimus | 8 | 2020 | 415 | 0.670 |
Why?
|
| Gene Expression Profiling | 5 | 2017 | 5159 | 0.660 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2023 | 612 | 0.660 |
Why?
|
| Hypopigmentation | 1 | 2018 | 28 | 0.660 |
Why?
|
| Skin Diseases | 2 | 2018 | 349 | 0.650 |
Why?
|
| Cadherins | 2 | 2022 | 660 | 0.630 |
Why?
|
| Radiation Oncology | 1 | 2023 | 529 | 0.630 |
Why?
|
| Pituitary Gland | 1 | 2018 | 150 | 0.610 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2022 | 600 | 0.600 |
Why?
|
| Radioisotopes | 4 | 2021 | 177 | 0.600 |
Why?
|
| Molecular Imaging | 1 | 2019 | 185 | 0.600 |
Why?
|
| Oncologists | 1 | 2019 | 134 | 0.590 |
Why?
|
| Indazoles | 9 | 2020 | 297 | 0.590 |
Why?
|
| Wearable Electronic Devices | 1 | 2018 | 105 | 0.590 |
Why?
|
| Indoles | 4 | 2016 | 1009 | 0.580 |
Why?
|
| Microbiota | 1 | 2023 | 547 | 0.580 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2021 | 387 | 0.580 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 214 | 0.580 |
Why?
|
| Neuroectodermal Tumors | 1 | 2016 | 35 | 0.580 |
Why?
|
| Heart Atria | 1 | 2019 | 352 | 0.570 |
Why?
|
| Skin Neoplasms | 7 | 2022 | 4654 | 0.570 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 234 | 0.570 |
Why?
|
| Jaundice | 1 | 2016 | 39 | 0.560 |
Why?
|
| Hyperbilirubinemia | 1 | 2016 | 78 | 0.560 |
Why?
|
| Survival Analysis | 17 | 2021 | 9180 | 0.560 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2021 | 328 | 0.560 |
Why?
|
| Combined Modality Therapy | 11 | 2023 | 8865 | 0.550 |
Why?
|
| Proteome | 1 | 2020 | 561 | 0.550 |
Why?
|
| Child | 23 | 2023 | 29154 | 0.550 |
Why?
|
| Pancreatic Neoplasms | 6 | 2023 | 5061 | 0.540 |
Why?
|
| Morpholines | 3 | 2022 | 289 | 0.540 |
Why?
|
| Internet | 4 | 2020 | 706 | 0.540 |
Why?
|
| Sequence Analysis, DNA | 4 | 2017 | 2483 | 0.540 |
Why?
|
| Neurofibromatosis 2 | 2 | 2014 | 32 | 0.540 |
Why?
|
| Mesenchymoma | 1 | 2015 | 14 | 0.530 |
Why?
|
| Hodgkin Disease | 3 | 2020 | 1429 | 0.530 |
Why?
|
| Yttrium Radioisotopes | 2 | 2020 | 178 | 0.530 |
Why?
|
| Genetic Testing | 6 | 2023 | 1589 | 0.530 |
Why?
|
| Lymphoma, Follicular | 1 | 2020 | 587 | 0.530 |
Why?
|
| Signal Transduction | 9 | 2019 | 11965 | 0.520 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 2023 | 334 | 0.520 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.520 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2018 | 406 | 0.520 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 544 | 0.520 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 715 | 0.520 |
Why?
|
| Headache | 1 | 2016 | 163 | 0.510 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 64 | 0.510 |
Why?
|
| Intestinal Neoplasms | 1 | 2016 | 189 | 0.500 |
Why?
|
| Therapies, Investigational | 2 | 2017 | 62 | 0.480 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 475 | 0.480 |
Why?
|
| Gene Amplification | 7 | 2022 | 731 | 0.480 |
Why?
|
| Microsatellite Instability | 4 | 2023 | 400 | 0.480 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 1341 | 0.480 |
Why?
|
| Ovarian Neoplasms | 4 | 2023 | 4638 | 0.470 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2024 | 1678 | 0.470 |
Why?
|
| Proportional Hazards Models | 9 | 2021 | 4988 | 0.470 |
Why?
|
| Breast Neoplasms | 7 | 2023 | 15694 | 0.470 |
Why?
|
| Receptor, ErbB-2 | 4 | 2023 | 2518 | 0.470 |
Why?
|
| Maximum Tolerated Dose | 13 | 2023 | 1290 | 0.460 |
Why?
|
| Pyriform Sinus | 1 | 2013 | 8 | 0.460 |
Why?
|
| Langerhans Cell Sarcoma | 1 | 2013 | 15 | 0.450 |
Why?
|
| Salvage Therapy | 4 | 2021 | 2054 | 0.450 |
Why?
|
| Phyllodes Tumor | 1 | 2013 | 62 | 0.450 |
Why?
|
| Gallbladder Neoplasms | 3 | 2023 | 245 | 0.450 |
Why?
|
| Drug Approval | 3 | 2022 | 178 | 0.440 |
Why?
|
| Prospective Studies | 12 | 2024 | 12873 | 0.440 |
Why?
|
| Adenocarcinoma | 4 | 2023 | 7789 | 0.440 |
Why?
|
| Receptors, Death Domain | 1 | 2012 | 7 | 0.440 |
Why?
|
| Doxorubicin | 5 | 2023 | 3005 | 0.440 |
Why?
|
| Neoplasm Staging | 17 | 2020 | 13658 | 0.440 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2013 | 82 | 0.440 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2020 | 1248 | 0.430 |
Why?
|
| Motion Pictures | 1 | 2012 | 23 | 0.420 |
Why?
|
| Fibroblast Growth Factors | 4 | 2022 | 257 | 0.420 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2020 | 6207 | 0.420 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2014 | 262 | 0.420 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 697 | 0.420 |
Why?
|
| Canada | 2 | 2023 | 429 | 0.420 |
Why?
|
| Cell Transdifferentiation | 1 | 2013 | 112 | 0.420 |
Why?
|
| Dendritic Cells | 1 | 2018 | 1085 | 0.410 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 3230 | 0.410 |
Why?
|
| Physicians | 1 | 2020 | 882 | 0.410 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2021 | 2488 | 0.410 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 205 | 0.410 |
Why?
|
| United States | 12 | 2023 | 15433 | 0.410 |
Why?
|
| Databases, Factual | 2 | 2018 | 2218 | 0.410 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2021 | 7551 | 0.410 |
Why?
|
| Disease Progression | 12 | 2021 | 6682 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2016 | 419 | 0.400 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 719 | 0.400 |
Why?
|
| Cell-Free Nucleic Acids | 3 | 2019 | 224 | 0.400 |
Why?
|
| Quinazolines | 5 | 2019 | 923 | 0.400 |
Why?
|
| Diphosphonates | 2 | 2010 | 262 | 0.400 |
Why?
|
| Holidays | 1 | 2011 | 6 | 0.400 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 622 | 0.390 |
Why?
|
| Lymphopenia | 2 | 2023 | 199 | 0.390 |
Why?
|
| Models, Molecular | 1 | 2016 | 1732 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2018 | 1533 | 0.390 |
Why?
|
| Survival Rate | 13 | 2021 | 12221 | 0.380 |
Why?
|
| Fathers | 1 | 2011 | 68 | 0.380 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 5 | 2024 | 355 | 0.380 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2023 | 665 | 0.380 |
Why?
|
| Uterine Neoplasms | 1 | 2015 | 545 | 0.380 |
Why?
|
| Sodium Fluoride | 2 | 2021 | 30 | 0.380 |
Why?
|
| Boron Compounds | 2 | 2021 | 59 | 0.380 |
Why?
|
| Follow-Up Studies | 17 | 2021 | 14889 | 0.370 |
Why?
|
| Testicular Neoplasms | 1 | 2014 | 529 | 0.370 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 2359 | 0.370 |
Why?
|
| Adolescent Health Services | 1 | 2010 | 36 | 0.370 |
Why?
|
| Frasier Syndrome | 1 | 2009 | 8 | 0.370 |
Why?
|
| Gonadoblastoma | 1 | 2009 | 9 | 0.370 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2010 | 26 | 0.370 |
Why?
|
| Attitude to Death | 1 | 2011 | 100 | 0.360 |
Why?
|
| Dysgerminoma | 1 | 2009 | 42 | 0.360 |
Why?
|
| Hypothalamic Neoplasms | 1 | 2009 | 21 | 0.360 |
Why?
|
| Positron-Emission Tomography | 4 | 2015 | 2173 | 0.360 |
Why?
|
| Biomarkers | 8 | 2023 | 5047 | 0.360 |
Why?
|
| Topotecan | 3 | 2023 | 239 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 1303 | 0.360 |
Why?
|
| Melanosis | 1 | 2010 | 16 | 0.360 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2010 | 18 | 0.360 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2010 | 121 | 0.360 |
Why?
|
| RNA-Binding Protein EWS | 3 | 2018 | 98 | 0.360 |
Why?
|
| DNA Mutational Analysis | 8 | 2017 | 2283 | 0.360 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2018 | 7702 | 0.360 |
Why?
|
| Professional-Family Relations | 1 | 2011 | 134 | 0.360 |
Why?
|
| Germ-Line Mutation | 3 | 2023 | 1046 | 0.360 |
Why?
|
| Genes, Wilms Tumor | 1 | 2009 | 64 | 0.360 |
Why?
|
| Cognition Disorders | 1 | 2015 | 786 | 0.350 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2019 | 2027 | 0.350 |
Why?
|
| Truth Disclosure | 1 | 2011 | 180 | 0.350 |
Why?
|
| RNA Splice Sites | 1 | 2009 | 111 | 0.350 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2023 | 3552 | 0.350 |
Why?
|
| Teratoma | 1 | 2011 | 236 | 0.350 |
Why?
|
| Hydrazines | 2 | 2021 | 208 | 0.340 |
Why?
|
| Comprehensive Health Care | 2 | 2020 | 49 | 0.340 |
Why?
|
| Severity of Illness Index | 5 | 2022 | 4320 | 0.330 |
Why?
|
| Tomography, Emission-Computed | 1 | 2010 | 310 | 0.330 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2022 | 182 | 0.330 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 6 | 2023 | 1331 | 0.330 |
Why?
|
| Pancytopenia | 2 | 2008 | 120 | 0.330 |
Why?
|
| Glycine | 2 | 2021 | 289 | 0.330 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 630 | 0.330 |
Why?
|
| Risk Assessment | 8 | 2021 | 6869 | 0.320 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2024 | 265 | 0.320 |
Why?
|
| Bone Density Conservation Agents | 1 | 2010 | 198 | 0.320 |
Why?
|
| Communication | 2 | 2012 | 876 | 0.320 |
Why?
|
| Drug Eruptions | 3 | 2019 | 256 | 0.320 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2008 | 63 | 0.310 |
Why?
|
| Mothers | 1 | 2011 | 410 | 0.310 |
Why?
|
| MAP Kinase Signaling System | 3 | 2021 | 848 | 0.310 |
Why?
|
| Adolescent Behavior | 1 | 2010 | 230 | 0.310 |
Why?
|
| Splenomegaly | 1 | 2008 | 158 | 0.310 |
Why?
|
| Mannose-Binding Lectin | 1 | 2007 | 8 | 0.310 |
Why?
|
| Splenectomy | 1 | 2008 | 158 | 0.310 |
Why?
|
| Carcinoma | 1 | 2019 | 2578 | 0.310 |
Why?
|
| Diarrhea | 4 | 2024 | 686 | 0.310 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2022 | 591 | 0.300 |
Why?
|
| Data Collection | 2 | 2020 | 620 | 0.290 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 1294 | 0.290 |
Why?
|
| Sarcoidosis | 1 | 2008 | 112 | 0.290 |
Why?
|
| Point Mutation | 1 | 2009 | 769 | 0.290 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2021 | 361 | 0.290 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 2927 | 0.290 |
Why?
|
| Diagnosis, Differential | 5 | 2024 | 4744 | 0.290 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2020 | 598 | 0.290 |
Why?
|
| Patient Selection | 6 | 2021 | 2055 | 0.290 |
Why?
|
| Tumor Microenvironment | 7 | 2022 | 2864 | 0.280 |
Why?
|
| United States Food and Drug Administration | 3 | 2022 | 332 | 0.280 |
Why?
|
| Niacinamide | 3 | 2014 | 421 | 0.270 |
Why?
|
| Capecitabine | 2 | 2018 | 388 | 0.270 |
Why?
|
| Retreatment | 2 | 2017 | 452 | 0.270 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 4 | 2022 | 160 | 0.270 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2021 | 388 | 0.270 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 441 | 0.270 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 764 | 0.260 |
Why?
|
| Erdheim-Chester Disease | 2 | 2018 | 53 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 2594 | 0.260 |
Why?
|
| Organoplatinum Compounds | 3 | 2017 | 702 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2021 | 4938 | 0.260 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 2 | 2015 | 68 | 0.250 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 538 | 0.250 |
Why?
|
| Deoxycytidine | 3 | 2023 | 1353 | 0.250 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 7548 | 0.250 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1265 | 0.240 |
Why?
|
| Phenylurea Compounds | 3 | 2014 | 580 | 0.240 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2023 | 447 | 0.240 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 918 | 0.240 |
Why?
|
| Comparative Effectiveness Research | 2 | 2021 | 126 | 0.240 |
Why?
|
| Genetic Association Studies | 3 | 2017 | 1084 | 0.240 |
Why?
|
| Receptors, Fibroblast Growth Factor | 2 | 2022 | 153 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2024 | 2054 | 0.240 |
Why?
|
| Cell Line, Tumor | 8 | 2020 | 14551 | 0.240 |
Why?
|
| Pandemics | 3 | 2023 | 1559 | 0.230 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 130 | 0.230 |
Why?
|
| Germany | 1 | 2023 | 111 | 0.230 |
Why?
|
| Transaminases | 2 | 2020 | 76 | 0.230 |
Why?
|
| Chylous Ascites | 1 | 2023 | 25 | 0.230 |
Why?
|
| Hydroxamic Acids | 3 | 2016 | 442 | 0.230 |
Why?
|
| European Union | 1 | 2023 | 18 | 0.230 |
Why?
|
| Paclitaxel | 3 | 2021 | 1996 | 0.230 |
Why?
|
| Bacterial Infections | 1 | 2007 | 479 | 0.230 |
Why?
|
| ras Proteins | 3 | 2017 | 770 | 0.230 |
Why?
|
| Fatigue | 3 | 2022 | 1239 | 0.220 |
Why?
|
| Mucositis | 1 | 2023 | 148 | 0.220 |
Why?
|
| Stress, Psychological | 1 | 2010 | 1000 | 0.220 |
Why?
|
| Malate Dehydrogenase | 1 | 2022 | 21 | 0.220 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2022 | 59 | 0.220 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2018 | 261 | 0.210 |
Why?
|
| CTLA-4 Antigen | 4 | 2021 | 657 | 0.210 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 153 | 0.210 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 6009 | 0.210 |
Why?
|
| Administration, Intravenous | 2 | 2020 | 249 | 0.210 |
Why?
|
| Multiprotein Complexes | 2 | 2015 | 395 | 0.210 |
Why?
|
| Stomach Neoplasms | 2 | 2014 | 2278 | 0.210 |
Why?
|
| Iodine Radioisotopes | 1 | 2024 | 371 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 3821 | 0.210 |
Why?
|
| Technetium Tc 99m Medronate | 2 | 2019 | 23 | 0.210 |
Why?
|
| Thrombocytopenia | 3 | 2023 | 846 | 0.210 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 227 | 0.210 |
Why?
|
| Osteoblastoma | 1 | 2021 | 15 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 8873 | 0.200 |
Why?
|
| Time Factors | 7 | 2021 | 12926 | 0.200 |
Why?
|
| Adenosine Triphosphate | 1 | 2024 | 571 | 0.200 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 2 | 2013 | 45 | 0.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2023 | 193 | 0.200 |
Why?
|
| Lymphoma | 2 | 2022 | 1467 | 0.200 |
Why?
|
| Anecdotes as Topic | 2 | 2011 | 11 | 0.200 |
Why?
|
| Liquid Biopsy | 2 | 2022 | 158 | 0.200 |
Why?
|
| BRCA2 Protein | 1 | 2023 | 358 | 0.200 |
Why?
|
| Child, Preschool | 8 | 2018 | 16273 | 0.200 |
Why?
|
| Proto-Oncogenes | 1 | 2021 | 202 | 0.200 |
Why?
|
| Cohort Studies | 6 | 2022 | 9244 | 0.200 |
Why?
|
| Phosphoramide Mustards | 1 | 2021 | 37 | 0.190 |
Why?
|
| Exons | 2 | 2021 | 1328 | 0.190 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2024 | 413 | 0.190 |
Why?
|
| Radiosurgery | 3 | 2020 | 1330 | 0.190 |
Why?
|
| Germ Cells | 1 | 2023 | 335 | 0.190 |
Why?
|
| Gene Frequency | 2 | 2023 | 1163 | 0.190 |
Why?
|
| Indium Radioisotopes | 1 | 2020 | 65 | 0.190 |
Why?
|
| Granulosa Cell Tumor | 1 | 2021 | 77 | 0.190 |
Why?
|
| Nitroimidazoles | 1 | 2021 | 100 | 0.190 |
Why?
|
| Mycobacterium Infections | 1 | 2020 | 49 | 0.190 |
Why?
|
| Abdomen, Acute | 1 | 2020 | 36 | 0.190 |
Why?
|
| Valine | 2 | 2018 | 176 | 0.190 |
Why?
|
| Quarantine | 1 | 2020 | 20 | 0.190 |
Why?
|
| CD40 Antigens | 1 | 2021 | 104 | 0.180 |
Why?
|
| BRCA1 Protein | 1 | 2023 | 493 | 0.180 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 2019 | 17 | 0.180 |
Why?
|
| Machine Learning | 1 | 2023 | 319 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2021 | 1048 | 0.180 |
Why?
|
| Eligibility Determination | 1 | 2020 | 77 | 0.180 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2020 | 222 | 0.180 |
Why?
|
| Models, Immunological | 1 | 2020 | 77 | 0.180 |
Why?
|
| Nausea | 2 | 2023 | 525 | 0.180 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2020 | 47 | 0.180 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2019 | 27 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 198 | 0.180 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2020 | 99 | 0.180 |
Why?
|
| Plant Oils | 1 | 2020 | 37 | 0.180 |
Why?
|
| Benzenesulfonates | 2 | 2011 | 195 | 0.180 |
Why?
|
| Triazoles | 2 | 2021 | 617 | 0.180 |
Why?
|
| Dyspnea | 2 | 2022 | 416 | 0.180 |
Why?
|
| Research | 1 | 2022 | 415 | 0.180 |
Why?
|
| Immunoglobulins | 1 | 2020 | 266 | 0.180 |
Why?
|
| Dermatitis, Phototoxic | 1 | 2019 | 6 | 0.180 |
Why?
|
| Cannabidiol | 1 | 2020 | 42 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2019 | 53 | 0.170 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 2315 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 140 | 0.170 |
Why?
|
| Public Opinion | 1 | 2020 | 83 | 0.170 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 194 | 0.170 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 166 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 3981 | 0.170 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2020 | 245 | 0.170 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 37 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 152 | 0.170 |
Why?
|
| Amino Acid Substitution | 2 | 2018 | 644 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 1547 | 0.170 |
Why?
|
| Drug Synergism | 4 | 2018 | 1313 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 1 | 2023 | 701 | 0.170 |
Why?
|
| Health Expenditures | 1 | 2021 | 211 | 0.170 |
Why?
|
| Angioplasty | 1 | 2019 | 94 | 0.170 |
Why?
|
| Dacarbazine | 3 | 2011 | 485 | 0.170 |
Why?
|
| Travel | 1 | 2020 | 190 | 0.170 |
Why?
|
| Inventions | 1 | 2018 | 37 | 0.160 |
Why?
|
| Palliative Care | 1 | 2010 | 2037 | 0.160 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2023 | 480 | 0.160 |
Why?
|
| Translocation, Genetic | 2 | 2017 | 1245 | 0.160 |
Why?
|
| Membrane Proteins | 3 | 2021 | 2819 | 0.160 |
Why?
|
| Organic Chemicals | 1 | 2018 | 113 | 0.160 |
Why?
|
| Research Design | 3 | 2020 | 1544 | 0.160 |
Why?
|
| Chondrosarcoma, Mesenchymal | 1 | 2018 | 17 | 0.160 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 365 | 0.160 |
Why?
|
| Drug Therapy | 1 | 2019 | 205 | 0.160 |
Why?
|
| Injections, Intralesional | 1 | 2018 | 164 | 0.160 |
Why?
|
| Consumer Health Information | 1 | 2018 | 52 | 0.160 |
Why?
|
| Spleen | 1 | 2020 | 676 | 0.160 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2019 | 311 | 0.160 |
Why?
|
| Apoptosis | 1 | 2012 | 7591 | 0.160 |
Why?
|
| Cetuximab | 2 | 2016 | 472 | 0.160 |
Why?
|
| Animals | 8 | 2023 | 59536 | 0.160 |
Why?
|
| Polyglutamic Acid | 1 | 2017 | 47 | 0.150 |
Why?
|
| Cell Adhesion | 1 | 2020 | 1008 | 0.150 |
Why?
|
| Workflow | 1 | 2018 | 275 | 0.150 |
Why?
|
| Genetic Variation | 2 | 2016 | 2086 | 0.150 |
Why?
|
| Hepatic Artery | 1 | 2018 | 240 | 0.150 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 246 | 0.150 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2017 | 43 | 0.150 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 172 | 0.150 |
Why?
|
| Texas | 6 | 2020 | 6311 | 0.150 |
Why?
|
| Mice | 6 | 2023 | 34495 | 0.150 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 4892 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 1085 | 0.150 |
Why?
|
| Immunologic Factors | 3 | 2017 | 649 | 0.150 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 524 | 0.150 |
Why?
|
| Leukemia, Lymphoid | 1 | 2017 | 276 | 0.150 |
Why?
|
| Carcinoma, Ductal | 1 | 2018 | 145 | 0.150 |
Why?
|
| Interleukin-12 | 1 | 2018 | 253 | 0.150 |
Why?
|
| Drug Administration Schedule | 6 | 2019 | 3472 | 0.150 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 223 | 0.150 |
Why?
|
| Valproic Acid | 2 | 2023 | 263 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2020 | 7226 | 0.150 |
Why?
|
| Tumor Burden | 2 | 2020 | 1987 | 0.140 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 1516 | 0.140 |
Why?
|
| Albumins | 1 | 2018 | 258 | 0.140 |
Why?
|
| Liver Diseases | 1 | 2022 | 574 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 4975 | 0.140 |
Why?
|
| International Cooperation | 1 | 2018 | 323 | 0.140 |
Why?
|
| Standard of Care | 1 | 2018 | 243 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 70 | 0.140 |
Why?
|
| Camptothecin | 2 | 2016 | 517 | 0.140 |
Why?
|
| Patient Positioning | 1 | 2018 | 195 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2022 | 799 | 0.140 |
Why?
|
| Medical Records | 1 | 2017 | 415 | 0.140 |
Why?
|
| Testis | 1 | 2020 | 717 | 0.140 |
Why?
|
| Hypertension | 3 | 2020 | 1503 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2022 | 3976 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2017 | 1742 | 0.140 |
Why?
|
| Mutation Rate | 1 | 2017 | 223 | 0.140 |
Why?
|
| Medical Informatics | 1 | 2018 | 198 | 0.140 |
Why?
|
| Interleukin-8 | 1 | 2018 | 519 | 0.140 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 634 | 0.140 |
Why?
|
| Psychometrics | 1 | 2020 | 937 | 0.140 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2015 | 123 | 0.140 |
Why?
|
| Off-Label Use | 1 | 2015 | 46 | 0.130 |
Why?
|
| Risk Factors | 7 | 2023 | 17523 | 0.130 |
Why?
|
| Carboplatin | 1 | 2018 | 823 | 0.130 |
Why?
|
| Drug Monitoring | 1 | 2017 | 333 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 502 | 0.130 |
Why?
|
| Proteus Syndrome | 1 | 2015 | 2 | 0.130 |
Why?
|
| Dermatitis, Photoallergic | 1 | 2015 | 5 | 0.130 |
Why?
|
| Alkaline Phosphatase | 1 | 2015 | 207 | 0.130 |
Why?
|
| Histiocytosis | 1 | 2015 | 54 | 0.130 |
Why?
|
| Mood Disorders | 1 | 2016 | 163 | 0.130 |
Why?
|
| Terminal Care | 1 | 2020 | 447 | 0.130 |
Why?
|
| Benzamides | 1 | 2020 | 1832 | 0.130 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2014 | 18 | 0.130 |
Why?
|
| Lung | 3 | 2023 | 3151 | 0.130 |
Why?
|
| Hospice Care | 1 | 2016 | 156 | 0.130 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2015 | 37 | 0.130 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1392 | 0.130 |
Why?
|
| Calcinosis | 1 | 2018 | 423 | 0.130 |
Why?
|
| Permeability | 1 | 2015 | 167 | 0.130 |
Why?
|
| Cancer Pain | 1 | 2020 | 312 | 0.130 |
Why?
|
| Esophageal Neoplasms | 2 | 2022 | 3168 | 0.130 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2014 | 27 | 0.130 |
Why?
|
| Vaccination | 1 | 2021 | 1123 | 0.120 |
Why?
|
| Exosomes | 1 | 2017 | 253 | 0.120 |
Why?
|
| Fever | 1 | 2017 | 497 | 0.120 |
Why?
|
| Incidence | 3 | 2020 | 5673 | 0.120 |
Why?
|
| Fanconi Anemia | 1 | 2015 | 88 | 0.120 |
Why?
|
| Platinum Compounds | 1 | 2014 | 131 | 0.120 |
Why?
|
| Aorta | 1 | 2018 | 692 | 0.120 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2015 | 115 | 0.120 |
Why?
|
| Dasatinib | 1 | 2017 | 862 | 0.120 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2015 | 132 | 0.120 |
Why?
|
| Patients | 1 | 2016 | 245 | 0.120 |
Why?
|
| Smad4 Protein | 1 | 2015 | 196 | 0.120 |
Why?
|
| Organophosphorus Compounds | 1 | 2014 | 101 | 0.120 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2013 | 17 | 0.120 |
Why?
|
| Tuberous Sclerosis | 1 | 2015 | 136 | 0.120 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2014 | 158 | 0.120 |
Why?
|
| Urogenital Neoplasms | 1 | 2014 | 108 | 0.110 |
Why?
|
| Tissue Distribution | 1 | 2015 | 875 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1165 | 0.110 |
Why?
|
| F-Box Proteins | 1 | 2014 | 96 | 0.110 |
Why?
|
| Somatomedins | 1 | 2013 | 75 | 0.110 |
Why?
|
| Echocardiography | 1 | 2019 | 1182 | 0.110 |
Why?
|
| S100 Proteins | 1 | 2014 | 181 | 0.110 |
Why?
|
| Neurofibromatosis 1 | 1 | 2014 | 144 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 2314 | 0.110 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 260 | 0.110 |
Why?
|
| Osteosclerosis | 1 | 2013 | 24 | 0.110 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2014 | 221 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2016 | 519 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2018 | 566 | 0.110 |
Why?
|
| Liver | 2 | 2020 | 2961 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2086 | 0.110 |
Why?
|
| Clonal Evolution | 1 | 2015 | 253 | 0.110 |
Why?
|
| WT1 Proteins | 1 | 2013 | 106 | 0.110 |
Why?
|
| B7-H1 Antigen | 4 | 2021 | 1022 | 0.110 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 191 | 0.110 |
Why?
|
| Imatinib Mesylate | 1 | 2017 | 1665 | 0.110 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 348 | 0.110 |
Why?
|
| Smoking | 1 | 2022 | 2440 | 0.110 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 324 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2020 | 806 | 0.110 |
Why?
|
| Global Health | 1 | 2018 | 657 | 0.110 |
Why?
|
| Registries | 1 | 2020 | 2170 | 0.110 |
Why?
|
| Anxiety | 1 | 2020 | 1179 | 0.110 |
Why?
|
| ErbB Receptors | 4 | 2023 | 2295 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2018 | 1152 | 0.110 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 593 | 0.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2023 | 521 | 0.100 |
Why?
|
| Pyrazines | 2 | 2016 | 495 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 1724 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 5437 | 0.100 |
Why?
|
| Economics | 1 | 2011 | 11 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1763 | 0.100 |
Why?
|
| Neuroimaging | 1 | 2015 | 403 | 0.100 |
Why?
|
| Neck | 1 | 2014 | 383 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 519 | 0.100 |
Why?
|
| Pneumonia | 1 | 2017 | 751 | 0.100 |
Why?
|
| Kidney | 1 | 2020 | 2146 | 0.100 |
Why?
|
| Administration, Oral | 4 | 2018 | 1544 | 0.100 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 336 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 1287 | 0.100 |
Why?
|
| Vinblastine | 2 | 2011 | 453 | 0.100 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 550 | 0.100 |
Why?
|
| Quality of Life | 3 | 2022 | 4532 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 691 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2014 | 469 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2012 | 324 | 0.090 |
Why?
|
| Mice, Nude | 1 | 2018 | 4307 | 0.090 |
Why?
|
| Phenotype | 2 | 2014 | 6295 | 0.090 |
Why?
|
| Microspheres | 1 | 2011 | 210 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 1 | 2014 | 423 | 0.090 |
Why?
|
| Myeloproliferative Disorders | 1 | 2017 | 767 | 0.090 |
Why?
|
| Carcinoma, Lobular | 1 | 2014 | 611 | 0.090 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2009 | 26 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1390 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 462 | 0.090 |
Why?
|
| Hemianopsia | 1 | 2009 | 42 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 986 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2011 | 231 | 0.090 |
Why?
|
| Speech Disorders | 1 | 2009 | 91 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2020 | 4078 | 0.090 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2009 | 70 | 0.090 |
Why?
|
| Proteinuria | 1 | 2009 | 155 | 0.090 |
Why?
|
| Cytokines | 1 | 2018 | 2809 | 0.080 |
Why?
|
| Cyclophosphamide | 3 | 2011 | 3001 | 0.080 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2008 | 36 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 854 | 0.080 |
Why?
|
| Bortezomib | 1 | 2010 | 543 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2010 | 362 | 0.080 |
Why?
|
| DNA, Neoplasm | 1 | 2014 | 1910 | 0.080 |
Why?
|
| Blood Cell Count | 1 | 2008 | 225 | 0.080 |
Why?
|
| Anemia | 2 | 2017 | 689 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2012 | 479 | 0.080 |
Why?
|
| Genome, Human | 1 | 2016 | 1869 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 543 | 0.080 |
Why?
|
| Memory | 1 | 2011 | 429 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 1216 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2008 | 355 | 0.070 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 1215 | 0.070 |
Why?
|
| Copper | 1 | 2008 | 165 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2010 | 1391 | 0.070 |
Why?
|
| Family | 1 | 2011 | 736 | 0.070 |
Why?
|
| Bleomycin | 1 | 2008 | 467 | 0.070 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 5687 | 0.070 |
Why?
|
| Lymph Node Excision | 1 | 2014 | 1959 | 0.070 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 4844 | 0.070 |
Why?
|
| Infant | 3 | 2017 | 13310 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2009 | 551 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 1493 | 0.070 |
Why?
|
| Cell Survival | 1 | 2012 | 3045 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 5539 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 992 | 0.070 |
Why?
|
| Prevalence | 3 | 2021 | 3260 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2011 | 1620 | 0.070 |
Why?
|
| Polyethylene Glycols | 2 | 2021 | 615 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 3343 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 2045 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 669 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 1879 | 0.060 |
Why?
|
| HIV-1 | 1 | 2009 | 653 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 1506 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 5767 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2008 | 1681 | 0.060 |
Why?
|
| Pain | 2 | 2022 | 1658 | 0.060 |
Why?
|
| Genes, erbB | 1 | 2023 | 26 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 4821 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 6915 | 0.060 |
Why?
|
| Guanosine Triphosphate | 1 | 2022 | 90 | 0.060 |
Why?
|
| Ukraine | 1 | 2022 | 18 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2009 | 1039 | 0.050 |
Why?
|
| Armed Conflicts | 1 | 2022 | 6 | 0.050 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2022 | 78 | 0.050 |
Why?
|
| Survivorship | 1 | 2023 | 109 | 0.050 |
Why?
|
| Brain | 1 | 2016 | 4113 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2008 | 1656 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 3890 | 0.050 |
Why?
|
| Models, Biological | 1 | 2011 | 3254 | 0.050 |
Why?
|
| Remission Induction | 1 | 2008 | 3569 | 0.050 |
Why?
|
| Antigen Presentation | 1 | 2022 | 272 | 0.050 |
Why?
|
| Cysteine | 1 | 2022 | 214 | 0.050 |
Why?
|
| Syndrome | 2 | 2015 | 1351 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2023 | 253 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 1586 | 0.050 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2021 | 17 | 0.050 |
Why?
|
| France | 1 | 2021 | 108 | 0.050 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2020 | 38 | 0.050 |
Why?
|
| Equivalence Trials as Topic | 1 | 2020 | 23 | 0.050 |
Why?
|
| Ischemia | 1 | 2023 | 391 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2021 | 85 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2017 | 2232 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 2104 | 0.050 |
Why?
|
| Hydrolases | 1 | 2021 | 123 | 0.050 |
Why?
|
| Mycobacterium | 1 | 2020 | 56 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2022 | 354 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 323 | 0.050 |
Why?
|
| Income | 1 | 2021 | 222 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2023 | 619 | 0.050 |
Why?
|
| Cyclin E | 1 | 2022 | 267 | 0.050 |
Why?
|
| Data Mining | 1 | 2020 | 88 | 0.050 |
Why?
|
| Solvents | 1 | 2020 | 66 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2020 | 181 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2008 | 2358 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 995 | 0.040 |
Why?
|
| Cisplatin | 2 | 2021 | 2432 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2022 | 639 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 4298 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 4314 | 0.040 |
Why?
|
| Safety | 1 | 2021 | 465 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 202 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 318 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 430 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2014 | 5542 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 754 | 0.040 |
Why?
|
| Abdomen | 1 | 2020 | 332 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2018 | 171 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 1555 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 2 | 2016 | 1121 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 4971 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 651 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2020 | 696 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2019 | 294 | 0.040 |
Why?
|
| Genome | 1 | 2021 | 672 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 498 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 573 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2020 | 369 | 0.040 |
Why?
|
| Curriculum | 1 | 2023 | 860 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 208 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1021 | 0.040 |
Why?
|
| Karyotype | 1 | 2017 | 234 | 0.040 |
Why?
|
| Elafin | 1 | 2017 | 34 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1945 | 0.040 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 2016 | 22 | 0.040 |
Why?
|
| Copper-transporting ATPases | 1 | 2016 | 44 | 0.040 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2016 | 22 | 0.040 |
Why?
|
| Cell-Free System | 1 | 2016 | 150 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2016 | 132 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2017 | 190 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2016 | 86 | 0.030 |
Why?
|
| Threonine | 1 | 2016 | 161 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2015 | 62 | 0.030 |
Why?
|
| Methionine | 1 | 2016 | 159 | 0.030 |
Why?
|
| Genes, p16 | 1 | 2015 | 125 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2015 | 114 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2021 | 4233 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2017 | 479 | 0.030 |
Why?
|
| Artifacts | 1 | 2018 | 532 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 334 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2009 | 5270 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 226 | 0.030 |
Why?
|
| Cation Transport Proteins | 1 | 2016 | 199 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Genes, erbB-2 | 1 | 2015 | 229 | 0.030 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2014 | 19 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2020 | 1145 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 128 | 0.030 |
Why?
|
| Transfection | 1 | 2020 | 2944 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2021 | 1026 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2021 | 1549 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 677 | 0.030 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2014 | 83 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 435 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 476 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 370 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2016 | 576 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2016 | 501 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 1360 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2014 | 183 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 672 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 1519 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 1972 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 370 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 660 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 1450 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 1162 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 4758 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 1869 | 0.030 |
Why?
|
| Arteriovenous Fistula | 1 | 2013 | 92 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 1094 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1217 | 0.030 |
Why?
|
| Software | 1 | 2018 | 1321 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 1033 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2015 | 1090 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2803 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5377 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2015 | 1442 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2014 | 543 | 0.020 |
Why?
|
| Interferons | 1 | 2011 | 291 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 189 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 2450 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2013 | 340 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 3033 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 212 | 0.020 |
Why?
|
| Procarbazine | 1 | 2009 | 69 | 0.020 |
Why?
|
| Kenya | 1 | 2009 | 46 | 0.020 |
Why?
|
| Lomustine | 1 | 2009 | 39 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 363 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 2316 | 0.020 |
Why?
|
| Uganda | 1 | 2009 | 74 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2009 | 101 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 1960 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 297 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2307 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 1258 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 6550 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2008 | 153 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2009 | 317 | 0.020 |
Why?
|
| Etoposide | 1 | 2009 | 870 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2011 | 510 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 2292 | 0.020 |
Why?
|
| Virus Replication | 1 | 2009 | 709 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 4804 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2008 | 668 | 0.020 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 821 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 2231 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2008 | 393 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2011 | 3842 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 4549 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 2370 | 0.010 |
Why?
|
| HIV Infections | 1 | 2009 | 2134 | 0.010 |
Why?
|